Publications

Coinfections/Superinfections – HAE models

Co-infection of the respiratory epithelium, scene of complex functional interactions between viral, bacterial, and human neuraminidases. Escuret V, Terrier O. Front Microbiol. 2023;14. doi: 10.3389/fmicb.2023.1137336.

The Activation of the RIG-I/MDA5 Signaling Pathway upon Influenza D Virus Infection Impairs the Pulmonary Proinflammatory Response Triggered by Mycoplasma bovis Superinfection. Gaudino M, Lion A, Sagné E, Nagamine B, Oliva J, Terrier O, Errazuriz-Cerda E, Scribe A, Sikht FZ, Simon E, Foret-Lucas C, Gausserès B, Lion J, Moreno A, Dordet-Frisoni E, Baranowski E, Volmer R, Ducatez MF, Meyer G. J Virol. 2023 Jan 24:e0142322. doi: 10.1128/jvi.01423-22

Interactions between Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Major Respiratory Viruses in Human nasal Epithelium. Pizzorno A, Padey B, Dulière V, Mouton W, Oliva J, Laurent E, Milesi C, Lina B, Traversier A, Julien T, Trouillet-Assant S, Rosa-Calatrava M, Terrier O. . J Infect Dis. 2022 Aug 29:jiac357. doi: 10.1093/infdis/jiac357

Flagellin From Pseudomonas aeruginosa Modulates SARS-CoV-2 Infectivity in Cystic Fibrosis Airway Epithelial Cells by Increasing TMPRSS2 Expression. Ruffin M, Bigot J, Calmel C, Mercier J, Givelet M, Oliva J, Pizzorno A, Rosa-Calatrava M, Corvol H, Balloy V, Terrier O and Guillot L. Front. Immunol. 12:714027. doi: 10.3389/fimmu.2021.714027

Viral and Bacterial Co-Infections in the Lungs: Dangerous Liaisons. Oliva, J.; Terrier, O. Viruses 2021, 13, 1725. https://doi.org/10.3390/v13091725

Transcriptional Profiling of Immune and Inflammatory Responses in the Context of SARS-CoV-2 Fungal Superinfection in a Human Airway Epithelial Model. Microorganisms. Nicolas de Lamballerie C, Pizzorno A, Fouret J, Szpiro L, Padey B, Dubois J, Julien T, Traversier A, Dulière V, Brun P, Lina B, Rosa-Calatrava M*, Terrier O*. 2020 Dec 11;8(12):1974. doi: 10.3390/microorganisms8121974.

Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples. Nicolas De Lamballerie C, Pizzorno A, Dubois J, Padey B, Julien T, Traversier A, Carbonneau J, Orcel E, Lina B, Hamelin ME, Roche M, Textoris J, Boivin G, Legras-Lachuer C, Terrier O*, Rosa-Calatrava M*. J Infect Dis. 2021 Mar 29;223(6):1052-1061. doi: 10.1093/infdis/jiaa468.

Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia. Nicolas de Lamballerie C, Pizzorno A, Dubois J, Julien T, Padey B, Bouveret M, Traversier A, Legras-Lachuer C, Lina B, Boivin G, Terrier O*, Rosa-Calatrava M*. Sci Rep. 2019 Aug 7;9(1):11493. doi: 10.1038/s41598-019-48013-7.

RSV Infection in Human Macrophages Promotes CXCL10/IP-10 Expression during Bacterial Co-Infection. Machado D, Hoffmann J, Moroso M, Rosa-Calatrava M, Endtz H, Terrier O, Paranhos-Baccalà G (TO & P-BG co-last authors). Int J Mol Sci. 2017 Dec 7;18(12):2654. doi: 10.3390/ijms18122654.

Viral and bacterial co-infection in severe pneumonia triggers innate immune responses and specifically enhances IP-10: a translational study. Hoffmann J, Machado D, Terrier O, Pouzol S, Messaoudi M, Basualdo W, Espínola EE, Guillen RM, Rosa-Calatrava M, Picot V, Bénet T, Endtz H, Russomando G, Paranhos-Baccalà G. Sci Rep. 2016 Dec 6;6:38532. doi: 10.1038/srep38532.

Drug Repurposing – Antimicrobial strategies

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro. Jonsdottir HR, Siegrist D, Julien T, Padey B, Bouveret M, Terrier O, Pizzorno A, Huang S, Samby K, Wells TNC, Boda B, Rosa-Calatrava M, Engler OB, Constant S.Biomed Pharmacother. 2022Jun;150:113058. doi: 10.1016/j.biopha.2022.113058.

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates. Marlin R, Desjardins D, Contreras V, Lingas G, Solas C, Roques P, Naninck T, Pascal Q, Behillil S, Maisonnasse P, Lemaitre J, Kahlaoui N, Delache B, Pizzorno A, Nougairede A, Ludot C, Terrier O, Dereuddre-Bosquet N, Relouzat F, Chapon C, Ho Tsong Fang R, van der Werf S, Rosa Calatrava M, Malvy D, de Lamballerie X, Guedj J, Le Grand R. Nat Commun. 2022 Aug 30;13(1):5108. doi: 10.1038/s41467-022-32565-w.

Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means. Terrier O, Slama-Schwok A. Adv Exp Med Biol. 2021;1322:195-218. doi: 10.1007/978-981-16-0267-2_8.

Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. Terrier O, Dilly S, Pizzorno A, Chalupska D, Humpolickova J, Bouřa E, Berenbaum F, Quideau S, Lina B, Fève B, Adnet F, Sabbah M, Rosa-Calatrava M, Maréchal V, Henri J, Slama-Schwok A. Molecules. 2021 Apr 29;26(9):2593. doi: 10.3390/molecules26092593.

In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. Checkmahomed L, Padey B, Pizzorno A, Terrier O, Rosa-Calatrava M, Abed Y, Baz M, Boivin G. Viruses. 2020 Oct 8;12(10):1139. doi: 10.3390/v12101139.

Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy. Pizzorno A, Padey B, Terrier O*, Rosa-Calatrava M*. Front Immunol. 2019 Mar 19;10:531. doi: 10.3389/fimmu.2019.00531.

Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures. Pizzorno A*, Terrier O*, Nicolas de Lamballerie C, Julien T, Padey B, Traversier A, Roche M, Hamelin ME, Rhéaume C, Croze S, Escuret V, Poissy J, Lina B, Legras-Lachuer C, Textoris J, Boivin G, Rosa-Calatrava M. Front Immunol. 2019 Jan 29;10:60. doi: 10.3389/fimmu.2019.00060.

SARS-CoV-2/COVID-19

Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges. Terrier O, Si-Tahar M, Ducatez M, Chevalier C, Pizzorno A, Le Goffic R, Crépin T, Simon G, Naffakh N.PLoS Pathog. 2021 Dec 30;17(12):e1010106. doi: 10.1371/journal.ppat.1010106.

Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection. Ferren M, Favède V, Decimo D, Iampietro M, Lieberman NAP, Weickert JL, Pelissier R, Mazelier M, Terrier O, Moscona A, Porotto M, Greninger AL, Messaddeq N, Horvat B, Mathieu C. Nat Commun. 2021 Oct 4;12(1):5809. doi: 10.1038/s41467-021-26096-z

Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. Asarnow D, Wang B, Lee WH, Hu Y, Huang CW, Faust B, Ng PML, Ngoh EZX, Bohn M, Bulkley D, Pizzorno A, Ary B, Tan HC, Lee CY, Minhat RA, Terrier O, Soh MK, Teo FJ, Yeap YYC, Seah SGK, Chan CEZ, Connelly E, Young NJ, Maurer-Stroh S, Renia L, Hanson BJ, Rosa-Calatrava M, Manglik A, Cheng Y, Craik CS, Wang CI. Cell. 2021 Jun 10;184(12):3192-3204.e16. doi: 10.1016/j.cell.2021.04.033.

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Pizzorno A, Padey B, Dubois J, Julien T, Traversier A, Dulière V, Brun P, Lina B, Rosa-Calatrava M, Terrier O. Antiviral Res. 2020 Sep;181:104878. doi: 10.1016/j.antiviral.2020.104878.

SARS-CoV-2 viral dynamics in non-human primates. Gonçalves A, Maisonnasse P, Donati F, Albert M, Behillil S, Contreras V, Naninck T, Marlin R, Solas C, Pizzorno A, Lemaitre J, Kahlaoui N, Terrier O, Ho Tsong Fang R, Enouf V, Dereuddre-Bosquet N, Brisebarre A, Touret F, Chapon C, Hoen B, Lina B, Rosa Calatrava M, de Lamballerie X, Mentré F, Le Grand R, van der Werf S, Guedj J. PLoS Comput Biol. 2021 Mar 17;17(3):e1008785. doi: 10.1371/journal.pcbi.1008785.

Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release. Eymieux S, Rouillé Y, Terrier O, Seron K, Blanchard E, Rosa-Calatrava M, Dubuisson J, Belouzard S, Roingeard P. Cell Mol Life Sci. 2021 Apr;78(7):3565-3576. doi: 10.1007/s00018-020-03745-y.

Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. Pizzorno A, Padey B, Julien T, Trouillet-Assant S, Traversier A, Errazuriz-Cerda E, Fouret J, Dubois J, Gaymard A, Lescure FX, Dulière V, Brun P, Constant S, Poissy J, Lina B, Yazdanpanah Y, Terrier O, Rosa-Calatrava M. Cell Rep Med. 2020 Jul 21;1(4):100059. doi: 10.1016/j.xcrm.2020.100059.

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, Naninck
T, Pizzorno A, Lemaitre J, Gonçalves A, Kahlaoui N, Terrier O, Fang RHT, Enouf V, Dereuddre-Bosquet N, Brisebarre A, Touret F, Chapon C, Hoen B, Lina B, Calatrava MR, van der Werf S, de Lamballerie X, Le Grand R. Nature. 2020 Sep;585(7826):584-587. doi: 10.1038/s41586-020-2558-4.

Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. Gonçalves A, Bertrand J, Ke R, Comets E, de Lamballerie X, Malvy D, Pizzorno A, Terrier O, Rosa Calatrava M, Mentré F, Smith P, Perelson AS, Guedj J. CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):509-514. doi: 10.1002/psp4.12543. Epub 2020 Aug 7.